Short Interest in ImmuCell Co. (NASDAQ:ICCC) Declines By 22.8%

ImmuCell Co. (NASDAQ:ICCC) was the target of a large decrease in short interest in March. As of March 15th, there was short interest totalling 13,200 shares, a decrease of 22.8% from the February 28th total of 17,100 shares. Based on an average trading volume of 8,000 shares, the short-interest ratio is presently 1.7 days. Approximately 0.2% of the shares of the company are short sold.

Institutional Investors Weigh In On ImmuCell

A number of hedge funds have recently added to or reduced their stakes in the stock. Mesirow Financial Investment Management Inc. grew its position in shares of ImmuCell by 100.0% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock worth $125,000 after acquiring an additional 12,178 shares during the last quarter. Citadel Advisors LLC bought a new position in ImmuCell in the 4th quarter worth about $149,000. Northern Trust Corp increased its stake in shares of ImmuCell by 51.0% in the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 14,982 shares during the period. Geode Capital Management LLC raised its holdings in shares of ImmuCell by 13.9% during the fourth quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock valued at $332,000 after buying an additional 7,878 shares during the last quarter. Finally, Dauntless Investment Group LLC acquired a new position in shares of ImmuCell during the fourth quarter worth approximately $676,000. 13.47% of the stock is currently owned by institutional investors.

ImmuCell Stock Performance

ImmuCell stock traded up $0.21 during mid-day trading on Tuesday, reaching $5.00. The company’s stock had a trading volume of 77,283 shares, compared to its average volume of 19,304. The company has a current ratio of 3.11, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36. ImmuCell has a twelve month low of $3.34 and a twelve month high of $5.82. The business has a 50 day moving average price of $5.11 and a 200-day moving average price of $4.47. The firm has a market cap of $44.56 million, a price-to-earnings ratio of -10.00 and a beta of 0.62.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings data on Tuesday, February 25th. The biotechnology company reported $0.06 earnings per share for the quarter. ImmuCell had a negative net margin of 15.99% and a negative return on equity of 15.32%. The business had revenue of $7.75 million during the quarter.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.